Key Takeaways
- Strong top line, margin floor set: Revenue grew 28% YoY on broad-based momentum, but EBITDA margin fell to 11.6%, a level management calls the base going forward.
- New products are now material contributors: Biosurfactants, NMMO, spray-cooled powders, fibre finishes and the vitamin premix plant have all begun contributing handsomely, validating the multi-year innovation pipeline.
- A ₹5 crore phenol hit masked underlying progress: A delayed China shipment forced spot buying at elevated prices; without it, the margin story would look cleaner, and management expects no repeat.
- The B2C exit is the clearest margin catalyst: Exiting the consumer business removes a structural drag, and management targets 15%+ consolidated EBITDA once the portfolio recalibration is complete, achievable in two years.
- What to watch next quarter: Whether the 11.6% margin floor actually holds, the pace of Thailand and pharma ramp-ups, and any concrete timeline on the B2C exit.
Top-Line Performance & Growth Drivers
- Broad-based 28% YoY growth: Domestic business sustained healthy momentum while exports grew 21% YoY, driven by deeper wallet share with strategic partners and new customer additions across key overseas markets.
- Volume-price split: YoY volume grew about 10%, with the remainder of growth coming from higher pricing, reflecting both pass-through of raw material costs and improved realizations.
- HPPC segment scale: The Home, Personal Care & Performance Chemicals segment crossed the ₹550 crore quarterly revenue milestone, reflecting increasing depth across applications and end-user industries.
- New products gaining traction: Products introduced over the last few years, including NMMO, MDEA, spray-cooled powders, biosurfactants, fibre finishes, and output from the vitamin premix plant, have started contributing handsomely to the top line.
- Growth despite EO constraints: New products driving growth include trace minerals, vitamin premixes and enzyme premixes in Animal Health and Nutrition; non-EO esters gaining volumes; NMMO, NMM and NFM gaining traction; and the Agro segment grew despite the lean season using non-ethoxylate raw materials.
- Institutional and B2C flat but improving: Growth remained flat YoY, but losses have moderated due to focus on improving product mix, enhancing operational efficiency, and maintaining cost discipline.
Edward Menezes: "I think the biosurfactants, the NMMO, the spray-cooled powders, the fibre finishes that we have introduced, as well as the vitamin premix plant which has become operational, all these have started contributing very handsomely to the top line now."
Margin Walk & Cost Headwinds
- EBITDA margin declined to 11.6%: Down from 12.5% YoY, reflecting the continued impact of the institutional and consumer businesses along with prevailing product mix and the cost environment.
- Phenol: a one-off ₹5 crore hit: Management did a larger block purchase anticipating prices would rise, but shipments from China were delayed by nearly one month, forcing spot buying at very high prices to supply customers. The market moved the other way.
- Freight costs a compounding drag: Freight prices rose due to geopolitical uncertainty and war; new orders were taken at prices factoring in previous freight levels, but freight has since increased again, causing incremental margin loss.
- Raw material pass-through works, but volatility hurts: Raw material price increases are being passed on without difficulty; the real issue is uncertainty from volatility and freight costs, which makes forward pricing and procurement decisions harder.
- Interest cost step-up: Interest cost rose this quarter because term loans related to CAPEX were previously capitalized; now that those CAPEX assets have come on stream, the interest cost is flowing through the P&L.
- Base business margin is healthier: Shorn of the B2C business, base business EBITDA margins are anywhere between 14% and 15%, depending on the year, quarter, and product mix.
- Seeding costs will not be sacrificed: Investments in new geographies like Saudi Arabia and in B2B marketing and distribution will continue; management will not stop these initiatives just to show a slightly higher EBITDA margin.
Ketan Sablok: "In anticipation that the prices would go up further, we did a slightly larger block of purchase, but then the market moved the other way."
Sunil Chari: "We will not stop seeding these initiatives just to show a slightly higher EBITDA margin."
Portfolio Reshaping: B2C Exit & Non-Core Monetization
- B2C exit underway, institutional business stays: The company will exit the B2C (consumer) business but will continue the institutional cleaning products business, which is the more profitable part. The exit removes a structural margin drag.
- Non-core asset monetization in motion: The sale of the Andheri office was completed as part of ongoing monetization of non-core and underutilized assets; management will continue to evaluate further opportunities in a calibrated manner.
- Portfolio rationalization broader than B2C: The company is evaluating rationalization of select non-core businesses and assets to simplify the portfolio and redeploy capital and management bandwidth toward higher-return opportunities.
- Andheri sale accounting nuance: The office was held in Unitop's name; when consolidation happened, assets were revalued five years back at the then-current market price, hence a lower profit was recognized in other income on the sale.
Sunil Chari: "Once you see the exit of some businesses which we are working very hard, you will definitely see the margin improvement."
Capacity Build-Out & New Initiatives
- Thailand greenfield blending plant operational: The small formulation unit generated only ₹2–₹3 crore in Q1, currently working on textile products only; the aim is to add Animal Health & Nutrition products and HPPC molecules in subsequent quarters.
- Pharma business: slow start, compliance gated: A few products started this quarter but ramp-up is slow due to long-drawn compliance processes; the target is to have most compliances done by end of Q2 or Q3, with ₹30–₹50 crore revenue potential for the current year.
- New R&D centre ramping up: Commissioned in the previous quarter, the centre is progressively ramping up, bringing research, product development, and application capabilities together on an integrated platform.
- Fibre Chemicals Division launched: A dedicated division now strengthens the textile specialty chemicals portfolio, expanding capabilities across the fibre-to-fibre value chain.
- India CAPEX slowing down: The company has slowed all CAPEX spends in India; only certain new products and molecules in R&D will proceed (pharma molecules, aroma chemicals); no large spends are intended this year and next year.
- MDEA plant ramp-up expected in 12 months: Ramping up should happen in the next 12 months, and management expects to definitely see higher margins from that asset.
Saudi Arabia: Long-Gestation Bet
- Project still in exploratory phase: Work is in progress with surveys underway and raw material/feedstock allocations and land allocations being formalized; nothing is finalized yet. Initial operational and exploratory pre-operative expenses have been incurred.
- Strategic rationale intact: The opportunity offers access to globally competitive raw materials and a well-developed petrochemical ecosystem; management's conviction in the long-term potential remains intact despite prevailing geographical uncertainty.
- Timeline and scope still undefined: Once an announcement is made, it should take about 1.5 years to start the first kilo of production. The product scope will be a mix of EO and non-EO products, wherever starting production offers the benefit of higher margins or higher realizations.
- Pre-operative expenses expected for a couple of years: Discussions are ongoing with partners, suppliers, project consultants, and the KSA ministry; the plan remains the same but no specific CAPEX figure or timeline was provided.
EO Dependency & the FY28 Inflection
- EO constraint still binding: The company remains dependent on a sole supplier in India for ethylene oxide, limiting its ability to negotiate on price and capping volume growth in EO-dependent chemistries.
- More EO expected by end of calendar year: Management expects additional EO availability before December, which would give a full year of benefit in FY28.
- FY28 should be better: With EO coming on stream by end of this calendar year, FY28 gets a full year with additional EO, plus ramp-up of capacities installed in areas without EO requirement during the current financial year.
- Non-EO capacity filling the gap: Capacities installed in areas that do not require EO will ramp up in the current financial year, supporting healthy growth even before the EO constraint eases.
- Scaling ambition: Management is looking at scaling up Rossari to more than double from here over the next four years, with the EO unlock and new capacities as the primary enablers.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin floor | 11.6% as the base level; margins not expected to go below this | Ongoing from Q1 FY27 |
| Consolidated EBITDA margin target | 15%+ at consolidated level | Achievable in two years |
| FY27 top-line growth | Around 15% | FY27 |
| B2C business exit | Exit the consumer business; institutional cleaning products business retained | No date given; "working very hard" |
| Pharma business ramp-up | Most compliances done; ₹30–₹50 crore revenue potential | End of Q2 or Q3 FY27 |
| MDEA plant ramp-up | Ramp-up with higher margins | Next 12 months |
| Additional EO availability | More EO supply coming on stream | Before December (end of calendar year) |
| KSA project first production | First kilo of production post-announcement | ~1.5 years from announcement date |
| Scaling target | More than double Rossari's size | Over the next four years |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹697.2 cr, +28% YoY, highest ever quarterly revenue |
| EBITDA | ₹80.6 cr, +18.7% YoY, highest ever quarterly EBITDA |
| EBITDA margin | 11.6%, vs 12.5% in Q1 FY26 |
| Core B2B EBITDA | ₹85 cr, +13% YoY, with EBITDA margin of approximately 14% |
| PAT | ₹35.1 cr, +4.5% YoY |
| HPPC segment revenue | Crossed ₹550 cr quarterly milestone |
| HPPC, TSC, AHN segment growth | ~28% YoY each |
| Exports | ~₹160 cr, 23%-24% of total revenue, +20%-21% YoY |
| Volume growth | ~10% YoY, rest of growth from higher pricing |
| Net debt | ₹248 cr, down from ₹280 cr in March 2026 |
| Interest cost run rate | ₹9 cr – ₹10 cr per quarter going forward |
| FY27 revenue growth guidance | ~15%, management sticking to earlier estimate |
| Pharma revenue target FY27 | ₹70 cr – ₹75 cr, up from more than ₹50 cr in FY26 |
| One-off phenol hit | ~₹5 cr impact on the quarter |
| EO capacity utilization | Practically 100% utilized except for small addition in batch reactors |